[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
![[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid Structure](CAS/20200119/GIF/1648843-04-2.gif)
- CAS No.
- 1648843-04-2
- Chemical Name:
- [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid
- Synonyms
- SX-682;SX-682, 10 mM in DMSO;2-[[[5-[(4-Fluorophenyl)carbamoyl]-2-pyrimidinyl]thio]methyl]-4-(trifluoromethoxy)phenylboronic Acid;(2-(((5-((4-fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid;[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid;Boronic acid, B-[2-[[[5-[[(4-fluorophenyl)amino]carbonyl]-2-pyrimidinyl]thio]methyl]-4-(trifluoromethoxy)phenyl]-;cells,SX-682,allosteric,SX 682,recruitment,suppressor,Inhibitor,tumor,CXCR,CXC chemokine receptors,SX682,immunity,MDSCs,inhibit,myeloid-derived,antitumor
- CBNumber:
- CB24840361
- Molecular Formula:
- C19H14BF4N3O4S
- Molecular Weight:
- 467.2
- MDL Number:
- MFCD28502254
- MOL File:
- 1648843-04-2.mol
[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid Properties
| Density | 1.53±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | -20°C |
| solubility | Soluble in DMSO (>25 mg/ml) |
| form | solid |
| pka | 8.18±0.53(Predicted) |
| color | Off-white |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| FDA UNII | H5212R2DPM |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0067128 | SX-682 98.52% | 1648843-04-2 | 5mg | $150 | 2021-12-16 | Buy |
| ChemScene | CS-0067128 | SX-682 98.52% | 1648843-04-2 | 10mg | $270 | 2021-12-16 | Buy |
| ChemScene | CS-0067128 | SX-682 98.52% | 1648843-04-2 | 25mg | $540 | 2021-12-16 | Buy |
| ChemScene | CS-0067128 | SX-682 98.52% | 1648843-04-2 | 50mg | $870 | 2021-12-16 | Buy |
| ChemScene | CS-0067128 | SX-682 98.52% | 1648843-04-2 | 100mg | $1300 | 2021-12-16 | Buy |
[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid Chemical Properties,Uses,Production
Description
SX-682 is a novel CXCR1/2 inhibitor (IC50s: CXCR1 = 42 nM, CXCR2 = 20 nM).1?It displayed robust synergistic activity with immune checkpoint blockade against castration resistant prostate cancer.2 It significantly reduced tumor burden in a Ptenfl/fl/Lkb1fl/fl mouse model of lung squamous cell cancer when used in combination with anti-PD1 therapy.3 SX-682 significantly inhibited trafficking of neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) enhancing anti-PD1 immune checkpoint blockade, T cell-based immunotherapy, and NK-cell immunotherapy.4,5
Uses
SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity[1].
in vivo
SX-682 (50 mg/kg; orally; twice a day on a Monday through Friday) has Meager to moderate effects as single agents on CRPC progression was observed, yet combination with ICB produced strong efficacy[2].
| Animal Model: | C57BL/6NTac-Tyrtm1Arte?female mice[2] |
| Dosage: | 50 mg/kg |
| Administration: | Orally; twice a day on a Monday through Friday |
| Result: | Has Meager to moderate effects on CRPC progression. |
IC 50
CXCR1; CXCR2
References
Zebala et al. (2015), WO2015/016938 Lu et al. (2017), Effective combinatorial immunotherapy for castration-resistant prostate cancer; Nature 542 728 Kargl et al. (2019), Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC; JCI Insight 4 e130850 Sun et al. (2019), Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy; JCI Insight 4 e126853 Greene et al. (2020), Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models; Clin. Cancer Res. 26 1420
[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid Preparation Products And Raw materials
Raw materials
Preparation Products
[2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 32268 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | laboratory@coreychem.com | China | 30230 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | sales@sarms4muscle.com | China | 10473 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38663 | 58 | |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| Wuhan Jingkang en Biomedical Technology Co., Ltd | +8613720134139 | orders@jknbiochem.com | China | 5221 | 58 |
| Changzhou Chenhong Biotechnology Co., Ltd. | 0519-85788828 13775037613 | sales@chemrenpharm.com | China | 3600 | 58 |
| WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd. | 17702719238 17702719238 | sales@sun-shinechem.com | China | 1042 | 64 |
| Shanghai Lollane Biological Technology Co.,Ltd. | 021-52996696，15000506266 15000506266 | China | 4611 | 55 |
